Mobile Health Technology for Palliative Care Patients

Mobile Health Technologies for Palliative Care Patients at the Interface of In-patient to Out-patient Care: A Feasibility Study Aiming to Early Predict Deterioration of Patient's Health Status

To test the potential and acceptance of wireless activity tracking in palliative care patients leaving hospital care. Explorative study, collaboration project of the Clinic of Radiation-Oncology, University Hospital Zurich and the Wearable Computing Laboratory, Swiss Federal Institut of Technology. Patients receive a tracking bracelet and a smart phone in order to gather objective physical activity parameters as step count, sleep duration, heart rate, social activity patterns (e.g. making calls) as well as subjective ratings of pain and distress. Quality of life (QoL) will be captured by paper questionnaire. Correlations between patients' physical activity patterns and the pain and distress level assessed from electronic scales as well as QoL-questionnaire will be performed. Acceptance will be evaluated by quantitative questionnaires and interviews. The proposed study is meant to be preparatory work for an intervention study to test the effect of wireless monitoring of palliative care patients on fostering early interventions for symptom relief and support of QoL.

Study Overview

• Status: Unknown
• Conditions: Chronic Disease; Metastatic Cancer; Mobile Health
• Intervention / Treatment: Device: Mobile Health

• Study Type: Observational
• Enrollment (Anticipated): 30

Contacts and Locations

Study Locations

• Switzerland
  • Zurich
    • Zürich, Zurich, Switzerland, 8091
      • Recruiting
      • Clinic of Radiation-Oncology University Hospital Zurich
      • Contact: Gudrun Theile, MD; Phone Number: +41 44 255 5495; Email: gudrun.theile@usz.ch
      • Contact: Matea Pavic, MD; Phone Number: +41 44 255 3015; Email: matea.pavic@usz.ch

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 105 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients hospitalized at one of the wards of the Clinic of Radiation-Oncology University Hospital Zurich, including a ward of specialized Palliative Care

Description

Inclusion Criteria:

• established diagnosis of metastatic cancer or other severe illness with limited life-expectancy (physicians guess <12 months, > 8 weeks)
• Karnofsky Index ≥50%
• ECOG≤ 2
• aged > 18 years
• passed a short handling test with devices (tracking bracelet, smart phone)

Exclusion Criteria:

• relevant cognitive impairment
• insufficient knowledge of German language.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feasibility (time of complete data transfer in weeks)	time of complete data transfer in weeks	12 weeks

Collaborators and Investigators

• Sponsor: University of Zurich
• Collaborators: Swiss Federal Institute of Technology; Swiss Academy of Medical Sciences (SAMS)
• Investigators: Study Chair: Matthias Guckenberger, Prof, Clinic of Radiation-Oncology USZ; Study Chair: Gerhard Tröster, Prof, ETH Zurich; Principal Investigator: Gudrun Theile, MD, Clinic of Radiation-Oncology USZ

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2017
• Primary Completion (Anticipated): May 31, 2018
• Study Completion (Anticipated): May 31, 2018

Study Registration Dates

• First Submitted: January 25, 2017
• First Submitted That Met QC Criteria: January 31, 2017
• First Posted (Estimate): February 1, 2017

Study Record Updates

• Last Update Posted (Actual): June 21, 2017
• Last Update Submitted That Met QC Criteria: June 20, 2017
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Chronic Disease
• Other Study ID Numbers: PC 16/16

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No